ALXN News and Press, Alexion Pharmaceuticals Inc. From 06/07/20

In my last article titled “ ACADIA: The company perspectives in numbers ”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I ...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 41 st Annual Global Goldman Sachs Healthcare Conference, taking place virtually on Tuesday, June 9th, 2020 at 1:20 p.m. ET. An audio webcast of the presentation will be available live. You can acces...

What a truly wild time to be an investor. Panic and uncertainty surrounding the coronavirus disease 2019 (COVID-19) pandemic initially sent the benchmark S&P 500 to its fastest bear market decline in history (it took only 17 trading sessions to fall at least 20% from its recent highs), and...

The stock market continued to gain ground at midday on Thursday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) participated in the modest rally. Slightly before noon EDT, the index was up just over half a percent, as was the Nasdaq 100 Index of top stocks on the exchange. There's been risi...

ARCA biopharma (NASDAQ: ABIO ) +59%  on launching AB201 program in COVID-19. More news on: ARCA biopharma, Inc., PhaseBio Pharmaceuticals, Inc., Technical Communications Corporation, Stocks on the move, , Read more ...

Shares of argenx (NASDAQ: ARGX) , a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. Investors excited about the future of argenx's lead candidate have pushed the stock 37.9% higher as of 12:38 p.m. EDT on Tuesday. ar...

On the heels of its meeting with the FDA, Apellis Pharmaceuticals (NASDAQ: APLS ) announces that it expects to file a marketing application in H2 seeking approval of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease in which the immune sys...

For much of the past three months, Wall Street has been taken on a once-in-a-lifetime ride . Panic surrounding the spread of the coronavirus disease 2019 (COVID-19) wound up pushing the benchmark S&P 500 down as much as 34% in just over a month. Although the market fiercely bounced back i...

Merger activity sputtered to a stop again last week with no new deals announced and one deal closing. This is the fifth week this year with no new deals announced. There were however some potential deals that were announced last week. On Monday, May 11, 2020, according to Bloomberg, Amazon.c...

Portola Pharmaceuticals (NASDAQ: PTLA ) is a $1.4 billion corporation that was recently acquired by Alexion Pharmaceuticals (NASDAQ: ALXN ). The two companies entered a definitive merger agreement, which we discussed and recommend reading about here . As we'll see throughout this article, r...